Acellular vaccines for ovine brucellosis: a safer alternative against a worldwide disease

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Expert Review of Vaccines

• Publication date

  2012-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/erv.11.172PMID 22149711
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An Oral Vaccine Based on U-Omp19 Induces Protection against B. abortus Mucosal Challenge by Inducing an Adaptive IL-17 Immune Response in Mice

  2011cited by this paper
• Poly(methyl vinyl ether-co-maleic anhydride) nanoparticles as innate immune system activators.

  2011cited by this paper
• Evaluation of the Safety and Immunogenicity in Rhesus Monkeys of a Recombinant Malaria Vaccine for Plasmodium vivax with a Synthetic Toll-Like Receptor 4 Agonist Formulated in an Emulsion

  2011cited by this paper
• Control of Brucella ovis infection in sheep.

  2011cited by this paper
• Protective Efficacy and Safety of Brucella melitensis 16MΔmucR against Intraperitoneal and Aerosol Challenge in BALB/c Mice

  2011cited by this paper
• Defending the mucosa: adjuvant and carrier formulations for mucosal immunity.

  2011cited by this paper
• B. melitensis rough strain B115 is protective against heterologous Brucella spp. infections.

  2011cited by this paper
• Immunological mechanisms of vaccination

  2011cited by this paper
• Brucellosis: a re-emerging zoonosis.

  2010cited by this paper
• Poly(Anhydride) Nanoparticles Act as Active Th1 Adjuvants through Toll-Like Receptor Exploitation

  2010cited by this paper
• Evaluation of particulate acellular vaccines against Brucella ovis infection in rams.

  2010cited by this paper
• Bioinformatics analysis of Brucella vaccines and vaccine targets using VIOLIN

  2010cited by this paper
• Nanotechnology solutions for mucosal immunization.

  2010cited by this paper
• Nondividing but Metabolically Active Gamma-Irradiated Brucella melitensis Is Protective against Virulent B. melitensis Challenge in Mice

  2009cited by this paper
• Brucellosis: the case for live, attenuated vaccines.

  2009cited by this paper
• Efficacy of bp26 and bp26/omp31 B. melitensis Rev.1 deletion mutants against Brucella ovis in rams.

  2009cited by this paper
• A novel nanoparticulate adjuvant for immunotherapy with Lolium perenne.

  2009cited by this paper
• ORAL VACCINATION WITH MICROENCAPSULED STRAIN 19 VACCINE CONFERS ENHANCED PROTECTION AGAINST BRUCELLA ABORTUS STRAIN 2308 CHALLENGE IN RED DEER (CERVUS ELAPHUS ELAPHUS)

  2009cited by this paper
• The polymeric antigen BLSOmp31 confers protection against Brucella ovis infection in rams.

  2009cited by this paper
• Immunoadjuvant capacity of flagellin and mannosamine-coated poly(anhydride) nanoparticles in oral vaccination.

  2009cited by this paper
• Nanoparticle vaccines against respiratory viruses

  2009cited by this paper
• Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine for site-specific delivery.

  2008cited by this paper
• Evaluation of Bioadhesive Capacity and Immunoadjuvant Properties of Vitamin B12-Gantrez Nanoparticles

  2008cited by this paper
• Brucella: a Mr "Hide" converted into Dr Jekyll.

  2008cited by this paper
• Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants

  2008cited by this paper
• Mucosal matters

  2008cited by this paper
• Immunization with Recombinant Brucella Species Outer Membrane Protein Omp16 or Omp19 in Adjuvant Induces Specific CD4+ and CD8+ T Cells as Well as Systemic and Oral Protection against Brucella abortus Infection

  2008cited by this paper
• Immunopathological responses and kinetics of Brucella melitensis Rev 1 infection after subcutaneous or conjunctival vaccination in rams.

  2008cited by this paper
• Allergen immunotherapy with nanoparticles containing lipopolysaccharide from Brucella ovis.

  2008cited by this paper
• Design opportunities for actively targeted nanoparticle vaccines.

  2008cited by this paper
• TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses.

  2008cited by this paper
• Evaluation of Brucella melitensis B115 as rough-phenotype vaccine against B. melitensis and B. ovis infections.

  2008cited by this paper
• The role of innate immune receptors in the control of Brucella abortus infection: toll-like receptors and beyond.

  2008cited by this paper
• Immunomodulatory biomaterials.

  2008cited by this paper
• Human Benefits of Animal Interventions for Zoonosis Control

  2007cited by this paper
• Adjuvants in vaccines and for immunisation: current trends

  2007cited by this paper
• A DNA vaccine coding for the chimera BLSOmp31 induced a better degree of protection against B. ovis and a similar degree of protection against B. melitensis than Rev.1 vaccination.

  2007cited by this paper
• Immunological responses and protective efficacy against Brucella melitensis induced by bp26 and omp31 B. melitensis Rev.1 deletion mutants in sheep.

  2007cited by this paper
• Risk of Transmission Associated With Live Attenuated Vaccines Given to Healthy Persons Caring for or Residing With an Immunocompromised Patient

  2007cited by this paper
• Perspectives for the Treatment of Brucellosis in the 21st Century: The Ioannina Recommendations

  2007cited by this paper
• A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination.

  2007cited by this paper
• Bioadhesive capacity and immunoadjuvant properties of thiamine-coated nanoparticles.

  2007cited by this paper
• Brucella spp. lumazine synthase: a novel adjuvant and antigen delivery system to effectively induce oral immunity.

  2006cited by this paper
• Brucella outer membrane complex-loaded microparticles as a vaccine against Brucella ovis in rams.

  2006cited by this paper
• Bioadhesive mannosylated nanoparticles for oral drug delivery.

  2006cited by this paper
• A Polymeric Bacterial Protein Activates Dendritic Cells via TLR41

  2006cited by this paper
• Bioadhesive Properties of Gantrez Nanoparticles

  2005cited by this paper
• Generation of improved mucosal vaccines by induction of innate immunity

  2005cited by this paper
• A DNA Vaccine Coding for the Brucella Outer Membrane Protein 31 Confers Protection against B. melitensis and B. ovis Infection by Eliciting a Specific Cytotoxic Response

  2005cited by this paper
• From the discovery of the Malta fever's agent to the discovery of a marine mammal reservoir, brucellosis has continuously been a re-emerging zoonosis.

  2005cited by this paper
• Subcellular fractions of Brucella ovis distinctively induce the production of interleukin-2, interleukin-4, and interferon-gamma in mice.

  2005cited by this paper
• Nanoparticles with specific bioadhesive properties to circumvent the pre-systemic degradation of fluorinated pyrimidines.

  2004cited by this paper
• Rough vaccines in animal brucellosis: structural and genetic basis and present status.

  2004cited by this paper
• Mannose receptor-targeted vaccines

  2004cited by this paper
• Vaccine adjuvants: Current state and future trends

  2004cited by this paper
• Brucella Lumazine Synthase Elicits a Mixed Th1-Th2 Immune Response and Reduces Infection in Mice Challenged with Brucella abortus 544 Independently of the Adjuvant Formulation Used

  2003cited by this paper
• The recombinant Omp31 from Brucella melitensis alone or associated with rough lipopolysaccharide induces protection against Brucella ovis infection in BALB/c mice.

  2003cited by this paper
• Origin, precursors and differentiation of mouse dendritic cells

  2003cited by this paper
• A DNA Vaccine Encoding Cu,Zn Superoxide Dismutase of Brucella abortus Induces Protective Immunity in BALB/c Mice

  2003cited by this paper
• Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro.

  2003cited by this paper
• Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice.

  2003cited by this paper
• Vaccine adjuvant technology: from mechanistic concepts to practical applications

  2003cited by this paper
• A DNA Vaccine Encoding Lumazine Synthase from Brucella abortus Induces Protective Immunity in BALB/c Mice

  2002cited by this paper
• Brucellosis vaccines: past, present and future.

  2002cited by this paper
• Brucella species lacking the major outer membrane protein Omp25 are attenuated in mice and protect against Brucella melitensis and Brucella ovis.

  2002cited by this paper
• Comparison of the efficacy of Brucella abortus strain RB51 and Brucella melitensis Rev. 1 live vaccines against experimental infection with Brucella melitensis in pregnant ewes.

  2001cited by this paper
• A Brucella ovis antigenic complex bearing poly-epsilon-caprolactone microparticles confer protection against experimental brucellosis in mice.

  2001cited by this paper
• Minor Nucleotide Substitutions in the omp31 Gene ofBrucella ovis Result in Antigenic Differences in the Major Outer Membrane Protein That It Encodes Compared to Those of the OtherBrucella Species

  2001cited by this paper
• Role of the mannose receptor in the immune response.

  2001cited by this paper
• Targeting polymerised liposome vaccine carriers to intestinal M cells.

  2001cited by this paper
• Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages?

  2001cited by this paper
• Recent advances in mucosal vaccine development.

  2000cited by this paper
• Reporte de primer caso humano de aislamiento y tipificación de Brucella abortus RB 51

  2000cited by this paper
• A review of the use of B. melitensis Rev 1 vaccine in adult sheep and goats.

  1997cited by this paper
• The Brucella abortus RB51 vaccine does not confer protection against Brucella ovis in rams.

  1995cited by this paper
• Modulation of immune responses in Balb/c mice vaccinated with Brucella abortus Cu-Zn superoxide dismutase synthetic peptide vaccine.

  1994cited by this paper
• Evaluation of whole cell and subcellular vaccines against Brucella ovis in rams.

  1993cited by this paper
• Brucella melitensis Rev-1 vaccine as a cause of human brucellosis.

  1993cited by this paper
• O-chain expression in the rough Brucella melitensis strain B115: induction of O-polysaccharide-specific monoclonal antibodies and intracellular localization demonstrated by immunoelectron microscopy.

  1992cited by this paper
• Biological properties of RB51; a stable rough strain of Brucella abortus.

  1991cited by this paper
• Comparison of subcutaneous and conjunctival routes of Rev 1 vaccination for the prophylaxis of Brucella ovis infection in rams.

  1990cited by this paper
• Protection of mice against Brucella abortus by immunization with polyclonal anti-idiotype antibodies.

  1990cited by this paper
• Comparative analyses of proteins extracted by hot saline or released spontaneously into outer membrane blebs from field strains of Brucella ovis and Brucella melitensis

  1989cited by this paper

• Evaluation of the efficacy of polymeric antigen BLSOmp31 formulated in a new cage-like particle adjuvant (ISPA YOLK) administered by parenteral or mucosal routes against Brucella ovis in rams.

  2025cites this paper
• Ocular Lesions in Brucella Infection: A Review of the Literature

  2022cites this paper
• Genome Sequencing and Comparative Genomics of Indian Isolates of Brucella melitensis

  2021cites this paper
• Disruption of pyruvate phosphate dikinase in Brucella ovis PA CO2-dependent and independent strains generates attenuation in the mouse model

  2020cites this paper
• Xyloglucan based mucosal nanovaccine for immunological protection against brucellosis developed by supercritical fluid technology

  2020cites this paper
• Oxidative Stress, Pathophysiology, and Immunity in Brucellosis

  2019cites this paper
• Induction of specific cell‐mediated immune responses and protection in BALB/c mice by vaccination with outer membrane vesicles from a Brucella melitensis human isolate

  2019cites this paper
• The CO2-dependence of Brucella ovis and Brucella abortus biovars is caused by defective carbonic anhydrases

  2018cites this paper
• Desarrollo de vacunas marcadas con GFP frente a la brucelosis ovina y tests diagnósticos asociados

  2017cites this paper
• Vaccines for Caprine Brucellosis: Status and Prospective

  2016cites this paper
• Vaccine Delivery Systems for Veterinary Immunization

  2014cites this paper
• Plant Based Edible Vaccines against Poultry Diseases: a Review

  2014cites this paper
• Toxoplasma gondii Exposure and the Risk of Schizophrenia

  2014cites this paper
• Mutants in the lipopolysaccharide of Brucella ovis are attenuated and protect against B. ovis infection in mice

  2014cites this paper
• A History of the Development of Brucella Vaccines

  2013cites this paper